Novo nabs FDA approval of a new drug for rare blood clotting disorder

John Carroll

Nordisk is ending the year with an from the FDA. The agency announced yesterday that it is giving the green light to a new therapy dubbed Tretten to treat an extremely known as congenital Factor XIII A-subunit deficiency.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS